JPWO2022003357A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022003357A5
JPWO2022003357A5 JP2023523681A JP2023523681A JPWO2022003357A5 JP WO2022003357 A5 JPWO2022003357 A5 JP WO2022003357A5 JP 2023523681 A JP2023523681 A JP 2023523681A JP 2023523681 A JP2023523681 A JP 2023523681A JP WO2022003357 A5 JPWO2022003357 A5 JP WO2022003357A5
Authority
JP
Japan
Prior art keywords
promoter
viral vector
sequence identity
pharmaceutical composition
isolated cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536008A5 (https=
JP2023536008A (ja
Publication date
Priority claimed from GBGB2010009.5A external-priority patent/GB202010009D0/en
Application filed filed Critical
Publication of JP2023536008A publication Critical patent/JP2023536008A/ja
Publication of JP2023536008A5 publication Critical patent/JP2023536008A5/ja
Publication of JPWO2022003357A5 publication Critical patent/JPWO2022003357A5/ja
Pending legal-status Critical Current

Links

JP2023523681A 2020-06-30 2021-06-30 ベクター Pending JP2023536008A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010009.5 2020-06-30
GBGB2010009.5A GB202010009D0 (en) 2020-06-30 2020-06-30 Vector
PCT/GB2021/051668 WO2022003357A1 (en) 2020-06-30 2021-06-30 Vector

Publications (3)

Publication Number Publication Date
JP2023536008A JP2023536008A (ja) 2023-08-22
JP2023536008A5 JP2023536008A5 (https=) 2024-07-08
JPWO2022003357A5 true JPWO2022003357A5 (https=) 2024-07-08

Family

ID=71949697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523681A Pending JP2023536008A (ja) 2020-06-30 2021-06-30 ベクター

Country Status (12)

Country Link
US (1) US20230175016A1 (https=)
EP (1) EP4172345A1 (https=)
JP (1) JP2023536008A (https=)
KR (1) KR20230056658A (https=)
CN (1) CN115997025A (https=)
AU (1) AU2021300616A1 (https=)
BR (1) BR112022026521A2 (https=)
CA (1) CA3183830A1 (https=)
GB (1) GB202010009D0 (https=)
IL (1) IL299505A (https=)
MX (1) MX2022016101A (https=)
WO (1) WO2022003357A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
AU2021293174A1 (en) 2020-06-14 2023-01-19 Vertex Pharmaceuticals Incorporated Complement Factor I-related compositions and methods
GB202217332D0 (en) * 2022-11-18 2023-01-04 Univ Bristol Methods
EP4410988A1 (en) * 2023-01-31 2024-08-07 Universitätsklinikum Hamburg-Eppendorf An aav2-vector variant for targeted transfer of genes
WO2024178007A1 (en) * 2023-02-21 2024-08-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mafb promoter for gene therapy for diabetes
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
AU2024262827A1 (en) * 2023-04-27 2025-10-16 Oregon Health & Science University Kidney-targeting aav capsids and methods of use thereof
GB202414499D0 (en) * 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332875A1 (en) 1996-10-17 1999-10-25 Oxford Biomedica Ltd Retroviral vectors
WO2005012351A2 (en) * 2003-08-01 2005-02-10 The Brigham And Women's Hospital, Inc. Novel functions for decay accelerating factor (daf) in inflammation
EP2357254A1 (en) * 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2457822T3 (es) * 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
ES2857773T5 (es) * 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
CN108291216B (zh) * 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット

Similar Documents

Publication Publication Date Title
JP2024054426A5 (https=)
JP2024095717A5 (https=)
JP2022500066A5 (https=)
JP2021502060A5 (https=)
JP2005521393A5 (https=)
JP2022066336A5 (https=)
US20260009041A1 (en) Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder
TW201629225A (zh) 第九因子基因療法
JPWO2022003357A5 (https=)
JPWO2020069461A5 (https=)
JP2024119830A5 (https=)
JP2020527167A5 (https=)
AU2001270631B2 (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
WO2019213011A1 (en) Compositions and methods for hemoglobin production
IL299374A (en) Polynucleotide
WO2006122242A2 (en) Compositions and methods for the treatment of inflammatory bowel disease utilizing nf-kb decoy polynucleotides
JP2019513395A5 (https=)
JPWO2022015715A5 (https=)
JP2020506695A5 (https=)
CN113573741B (zh) 修饰腺病毒和含有其的医药
JP2019514401A5 (https=)
RU2018142797A (ru) Средства для лечения инфекции вируса гепатита в (hbv) и их применение
JPWO2020061528A5 (https=)
JPWO2022016055A5 (https=)
WO2021188058A1 (en) Molecular systems and therapies using the same